MIB Agents Family Funds support research through our annual OutSmarting Osteosarcoma research grant program. Since launching in 2017, MIB Agents Family Funds have awarded $2.5 million in osteosarcoma research funding, supporting 32 investigators. In 2022, we introduced a dedicated Young Investigator Grant, and since then, we’re proud to have supported 14 early-career scientists driving progress in the field.
SEE FUNDED RESEARCHLaunched in 2017 and powered by MIB Agents Family Funds, the OutSmarting Osteosarcoma Research Grant has fueled discovery by awarding $2.5 million to 32 dedicated investigators working to advance osteosarcoma research. But the impact of this investment extends far beyond these studies. As a result of OutSmarting Osteosarcoma's investment, MIB Agents funded studies have resulted in:
.png)
159 Presentations sharing findings with the scientific community
.png)
19 Publications disseminating findings into the public domain
.png)
7 clinical trials opened
.png)
$21.1 million secured in additional osteosarcoma research funding
OutSmarting Osteosarcoma 2025 Hero Grant Because of Sydney
David Ulmert, MD, PhD | University of California, Los Angeles
High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches
OutSmarting Osteosarcoma 2024 Hope YI Grant Because of Sydney
Arianexys Aquino-López, MD, PhD | Baylor College of Medicine
Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma
OutSmarting Osteosarcoma 2023 Hope YI Grant Because of Sydney
Marta Roman Moreno, PhD | University of California, San Francisco
CRISPRi screening to identify vulnerabilities in metastatic osteosarcoma
OutSmarting Osteosarcoma 2025 Hope YI Grant in partnership with the RISE Foundation, Because of Reese
Andrew S. Clugston, PhD | University of California, San Francisco Oncogenic structural variation in the genome of pediatric osteosarcoma
OutSmarting Osteosarcoma 2023 Hope YI Grant Because of Sydney
Marta Roman Moreno, PhD | University of California, San Francisco
CRISPRi screening to identify vulnerabilities in metastatic osteosarcoma
